Literature DB >> 23723950

8,15-Dioxa-10,13-di-aza-tetra-cyclo-[14.4.0.0(2,7).0(9,14)]icosa-1(16),2,4,6,9(14),10,12,17,19-nona-ene.

Thothadri Srinivasan1, Venkatesan Kalpana, Perumal Rajakumar, Devadasan Velmurugan.   

Abstract

The asymmetric unit of the title compound, C16H10N2O2, contains one half-mol-ecule, the complete mol-ecule being generated by twofold rotation symmetry. The plane of the pyrazine ring forms a dihedral angle of 64.87 (6)° with that of the benzene ring, and the planes of the two benzene rings are inclined to one another by 54.20 (6)°. The O atom deviates from the plane of the benzene ring by 0.1549 (8) Å. There are no significant inter-molecular inter-actions in the crystal.

Entities:  

Year:  2013        PMID: 23723950      PMCID: PMC3648330          DOI: 10.1107/S1600536813011318

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For applications of the pyrazine ring system in drug development, see: Du et al. (2009 ▶); Dubinina et al. (2006 ▶); Ellsworth et al. (2007 ▶); Mukaiyama et al. (2007 ▶). For background to the fluorescence properties of related compounds, see: Kawai et al. (2001 ▶); Abdullah (2005 ▶) and for their biological activity, see: Seitz et al. (2002 ▶); Temple et al. (1970 ▶). For a related structure, see: Nasir et al. (2010 ▶).

Experimental

Crystal data

C16H10N2O2 M = 262.26 Orthorhombic, a = 14.429 (3) Å b = 10.162 (2) Å c = 8.3313 (18) Å V = 1221.6 (4) Å3 Z = 4 Mo Kα radiation μ = 0.10 mm−1 T = 293 K 0.30 × 0.25 × 0.20 mm

Data collection

Bruker SMART APEXII area-detector diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2008 ▶) T min = 0.972, T max = 0.981 6082 measured reflections 1502 independent reflections 1226 reflections with I > 2σ(I) R int = 0.029

Refinement

R[F 2 > 2σ(F 2)] = 0.033 wR(F 2) = 0.106 S = 1.03 1502 reflections 92 parameters H-atom parameters constrained Δρmax = 0.22 e Å−3 Δρmin = −0.13 e Å−3 Data collection: APEX2 (Bruker, 2008 ▶); cell refinement: SAINT (Bruker, 2008 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012 ▶) and Mercury (Macrae et al., 2008 ▶); software used to prepare material for publication: SHELXL97 and PLATON (Spek, 2009 ▶). Click here for additional data file. Crystal structure: contains datablock(s) global, I. DOI: 10.1107/S1600536813011318/su2586sup1.cif Click here for additional data file. Structure factors: contains datablock(s) I. DOI: 10.1107/S1600536813011318/su2586Isup2.hkl Click here for additional data file. Supplementary material file. DOI: 10.1107/S1600536813011318/su2586Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C16H10N2O2F(000) = 544
Mr = 262.26Dx = 1.426 Mg m3
Orthorhombic, PbcnMo Kα radiation, λ = 0.71073 Å
Hall symbol: -P 2n 2abCell parameters from 1502 reflections
a = 14.429 (3) Åθ = 2.5–28.3°
b = 10.162 (2) ŵ = 0.10 mm1
c = 8.3313 (18) ÅT = 293 K
V = 1221.6 (4) Å3Block, colourless
Z = 40.30 × 0.25 × 0.20 mm
Bruker SMART APEXII area-detector diffractometer1502 independent reflections
Radiation source: fine-focus sealed tube1226 reflections with I > 2σ(I)
Graphite monochromatorRint = 0.029
ω and φ scansθmax = 28.3°, θmin = 2.5°
Absorption correction: multi-scan (SADABS; Bruker, 2008)h = −18→19
Tmin = 0.972, Tmax = 0.981k = −5→13
6082 measured reflectionsl = −7→10
Refinement on F2Secondary atom site location: difference Fourier map
Least-squares matrix: fullHydrogen site location: inferred from neighbouring sites
R[F2 > 2σ(F2)] = 0.033H-atom parameters constrained
wR(F2) = 0.106w = 1/[σ2(Fo2) + (0.0544P)2 + 0.1721P] where P = (Fo2 + 2Fc2)/3
S = 1.03(Δ/σ)max < 0.001
1502 reflectionsΔρmax = 0.22 e Å3
92 parametersΔρmin = −0.13 e Å3
0 restraintsExtinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4
Primary atom site location: structure-invariant direct methodsExtinction coefficient: 0.012 (3)
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2sigma(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
C10.53624 (10)1.14890 (12)0.19682 (18)0.0623 (4)
H10.56001.22890.16160.075*
C20.53746 (8)0.92738 (11)0.19677 (13)0.0426 (3)
C30.60493 (7)0.71770 (11)0.24296 (13)0.0395 (3)
C40.54878 (7)0.61036 (10)0.27797 (12)0.0390 (3)
C50.58736 (8)0.50933 (12)0.36919 (14)0.0480 (3)
H50.55230.43490.39220.058*
C60.67748 (9)0.51846 (14)0.42609 (16)0.0568 (4)
H60.70200.45090.48830.068*
C70.73073 (8)0.62674 (15)0.39094 (15)0.0594 (4)
H70.79080.63280.43050.071*
C80.69529 (8)0.72654 (12)0.29713 (15)0.0505 (3)
H80.73170.79890.27060.061*
N10.57395 (7)1.03683 (10)0.14200 (14)0.0546 (3)
O10.57275 (5)0.81298 (8)0.13462 (9)0.0446 (2)
U11U22U33U12U13U23
C10.0751 (9)0.0430 (6)0.0688 (9)−0.0077 (6)−0.0246 (6)0.0065 (6)
C20.0464 (6)0.0431 (6)0.0383 (6)−0.0018 (4)−0.0088 (4)0.0017 (4)
C30.0383 (5)0.0458 (5)0.0344 (5)0.0021 (4)0.0021 (4)−0.0019 (4)
C40.0382 (5)0.0429 (5)0.0357 (5)0.0033 (4)0.0052 (4)−0.0026 (4)
C50.0498 (6)0.0476 (6)0.0467 (6)0.0092 (5)0.0103 (5)0.0029 (5)
C60.0547 (7)0.0697 (8)0.0461 (6)0.0241 (6)0.0024 (5)0.0049 (6)
C70.0417 (6)0.0870 (10)0.0496 (7)0.0130 (6)−0.0066 (5)−0.0073 (7)
C80.0394 (6)0.0623 (7)0.0497 (7)−0.0040 (5)−0.0005 (5)−0.0078 (6)
N10.0593 (6)0.0495 (6)0.0548 (6)−0.0094 (5)−0.0118 (5)0.0090 (5)
O10.0486 (5)0.0467 (4)0.0384 (4)−0.0009 (3)0.0040 (3)0.0041 (3)
C1—N11.3423 (17)C4—C51.3935 (16)
C1—C1i1.371 (3)C4—C4i1.483 (2)
C1—H10.9300C5—C61.3871 (17)
C2—N11.3124 (15)C5—H50.9300
C2—O11.3707 (14)C6—C71.374 (2)
C2—C2i1.398 (2)C6—H60.9300
C3—C81.3826 (15)C7—C81.3787 (18)
C3—C41.3897 (15)C7—H70.9300
C3—O11.4029 (13)C8—H80.9300
N1—C1—C1i121.95 (8)C6—C5—H5119.6
N1—C1—H1119.0C4—C5—H5119.6
C1i—C1—H1119.0C7—C6—C5120.33 (12)
N1—C2—O1116.01 (10)C7—C6—H6119.8
N1—C2—C2i122.05 (7)C5—C6—H6119.8
O1—C2—C2i121.79 (6)C6—C7—C8120.18 (11)
C8—C3—C4122.16 (11)C6—C7—H7119.9
C8—C3—O1118.51 (10)C8—C7—H7119.9
C4—C3—O1118.93 (9)C7—C8—C3119.14 (11)
C3—C4—C5117.38 (10)C7—C8—H8120.4
C3—C4—C4i119.18 (8)C3—C8—H8120.4
C5—C4—C4i123.41 (8)C2—N1—C1115.99 (12)
C6—C5—C4120.77 (12)C2—O1—C3117.73 (8)
C8—C3—C4—C5−0.82 (16)C4—C3—C8—C7−0.97 (17)
O1—C3—C4—C5171.84 (9)O1—C3—C8—C7−173.66 (10)
C8—C3—C4—C4i177.25 (11)O1—C2—N1—C1176.77 (10)
O1—C3—C4—C4i−10.09 (16)C2i—C2—N1—C11.3 (2)
C3—C4—C5—C61.84 (16)C1i—C1—N1—C2−0.2 (2)
C4i—C4—C5—C6−176.15 (12)N1—C2—O1—C3126.38 (10)
C4—C5—C6—C7−1.07 (18)C2i—C2—O1—C3−58.13 (16)
C5—C6—C7—C8−0.78 (19)C8—C3—O1—C2−86.29 (12)
C6—C7—C8—C31.78 (18)C4—C3—O1—C2100.77 (11)
  9 in total

1.  Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.

Authors:  Harunobu Mukaiyama; Toshihiro Nishimura; Satoko Kobayashi; Tomonaga Ozawa; Noboru Kamada; Yoshimitsu Komatsu; Shinji Kikuchi; Hideki Oonota; Hiroshi Kusama
Journal:  Bioorg Med Chem       Date:  2006-10-24       Impact factor: 3.641

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

3.  Synthesis of potential antimalarial agents. VI. Preparation of 3-(p-chlorophenyl)-8-(4-(diethylamino)-1-methylbutyl()amino) pyrido(2,3-b)pyrazine.

Authors:  C Temple; J D Rose; J A Montgomery
Journal:  J Med Chem       Date:  1970-11       Impact factor: 7.446

4.  Synthesis and antimycobacterial activity of pyrazine and quinoxaline derivatives.

Authors:  Lainne E Seitz; William J Suling; Robert C Reynolds
Journal:  J Med Chem       Date:  2002-12-05       Impact factor: 7.446

5.  Novel 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitriles, the promising protein kinase inhibitors with antiproliferative activity.

Authors:  G G Dubinina; M O Platonov; S M Golovach; P O Borysko; A O Tolmachov; Y M Volovenko
Journal:  Eur J Med Chem       Date:  2006-05-03       Impact factor: 6.514

6.  Imidazo-pyrazine derivatives as potent CXCR3 antagonists.

Authors:  Xiaohui Du; Darin J Gustin; Xiaoqi Chen; Jason Duquette; Lawrence R McGee; Zhulun Wang; Karen Ebsworth; Kirk Henne; Bryan Lemon; Ji Ma; Shichang Miao; Emmanuel Sabalan; Timothy J Sullivan; George Tonn; Tassie L Collins; Julio C Medina
Journal:  Bioorg Med Chem Lett       Date:  2009-07-09       Impact factor: 2.823

7.  Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.

Authors:  Bruce A Ellsworth; Ying Wang; Yeheng Zhu; Annapurna Pendri; Samuel W Gerritz; Chongqing Sun; Kenneth E Carlson; Liya Kang; Rose A Baska; Yifan Yang; Qi Huang; Neil T Burford; Mary Jane Cullen; Susan Johnghar; Kamelia Behnia; Mary Ann Pelleymounter; William N Washburn; William R Ewing
Journal:  Bioorg Med Chem Lett       Date:  2007-04-29       Impact factor: 2.823

8.  2-(3-Meth-oxy-phen-oxy)pyrimidine.

Authors:  Shah Bakhtiar Nasir; Zanariah Abdullah; Zainal A Fairuz; Seik Weng Ng; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-07-31

9.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.